Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
March 08 2022 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), an early
commercial-stage biopharmaceutical company leading a new treatment
paradigm to improve the lives of patients suffering from pruritus,
today announced biomarker data from the KARE Phase 2 clinical trial
evaluating Oral KORSUVA™ (difelikefalin) for the treatment of
moderate-to-severe pruritus in atopic dermatitis patients will be
presented in a late-breaking oral presentation at the 2022 American
Academy of Dermatology (AAD) Annual Meeting, to be held March
25-29, 2022, in Boston, MA.
Details for the late-breaking oral presentation
are as follows:
Title: Oral Difelikefalin
Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis
Subjects With Moderate-to-Severe PruritusSession:
S026 – Late-Breaking Research: Clinical Trials
Date and Time: Saturday, March 26, 2022, 9:40 a.m.
ETLocation: Room 210APresenter:
Paola Facheris, MD, Icahn School of Medicine at Mount Sinai, New
York, NY; Department of Biomedical Sciences, Humanitas University,
Pieve Emanuele, Italy
Virtual R&D Event
As previously announced, Cara Therapeutics will
be hosting a virtual R&D event at 1:00 p.m. ET on March 11,
2022, which will focus on the initiation of Oral KORSUVA
(difelikefalin) Phase 3 programs for the treatment of pruritus in
patients with non-dialysis dependent advanced chronic kidney
disease and atopic dermatitis, respectively. An interactive Q&A
session will follow the presentation. Presenters will include:
- Christopher Posner, President &
Chief Executive Officer and Director of Cara Therapeutics
- Joana Goncalves, MD, Chief Medical
Officer of Cara Therapeutics
- Brian Kim, MD, MTR, Icahn School of
Medicine at Mount Sinai, NY
- Jonathan Silverberg, MD, PhD, MPH,
George Washington University School of Medicine and Health
Sciences
A live audio webcast of the presentation and
accompanying slides will be accessible under “Events &
Presentations” in the News & Investors section of the Company’s
website at www.CaraTherapeutics.com. A replay of the webcast will
be archived on the Company’s website following the
presentation.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s novel KORSUVA™ (difelikefalin) injection is the first and
only FDA-approved treatment for moderate-to-severe pruritus
associated with chronic kidney disease in adults undergoing
hemodialysis. The Company is developing an oral formulation of
difelikefalin and plans to initiate Phase 3 programs in the first
quarter of 2022 for the treatment of pruritus in patients with
non-dialysis-dependent advanced chronic kidney disease and
atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin)
are ongoing in primary biliary cholangitis and notalgia
paresthetica patients with moderate-to-severe pruritus. For more
information, visit www.CaraTherapeutics.com and follow the company
on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024